Trials / Withdrawn
WithdrawnNCT05719012
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19: a Randomized, Double-blind, Parallel-controlled Study
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Shanghai East Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UC-MSCs | Intravenous injection three times with one-month interval |
Timeline
- Start date
- 2023-04-01
- Primary completion
- 2023-12-01
- Completion
- 2024-03-30
- First posted
- 2023-02-08
- Last updated
- 2023-11-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05719012. Inclusion in this directory is not an endorsement.